|

BL-M11D1 Clinical Trials

3 actively recruiting trials across 1 location

▲ +1 trial since August 2026

Pipeline

Phase 1: 2Phase 2/3: 1

Top Sponsors

  • Sichuan Baili Pharmaceutical Co., Ltd.2
  • SystImmune Inc.1

Indications

  • Cancer3
  • Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)1
  • Relapsed/Refractory Acute Myeloid Leukemia1
  • Acute Myeloid Leukemia1

Other2 trials

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Phase 2/3
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1

Duarte, California1 trial

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

City of Hope

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.